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speciﬁc quality criteria developed by the authors. RESULTS: We
found 45 comparative studies in 43 publications. Asthma (14
studies) and psychiatric illness (12 studies) were most commonly
investigated. In 33 studies, interventions were educational, 20
had multiple components and 23 did not appear to be linked to
proven reasons for non-adherence. No studies assessed manage-
ment of unintentional non-adherence. No study met all quality
criteria. Study quality has not improved with time, as some better
studies are over ten years old. Many studies used inadequate or
unidentiﬁable adherence measures. Critically, many were too
small or not randomised. All studies assumed that patients were
prescribed appropriate therapy for their condition, and no
assessment of treatment quality was made by any study. Report-
ing of adherence and outcome results was often unclear. Cost
data were poorer quality than outcome data, using average or
estimated costs and omitting some cost elements. Nine studies
carried out incremental economic analysis. CONCLUSIONS:
We were not able to make deﬁnitive conclusions about the cost-
effectiveness of medication adherence enhancing interventions
due to the heterogeneity of the studies found and incomplete
reporting of results. Important policy decisions need to be made
about non-adherence, however, they are currently being made in
a vacuum of adequate information. Medication adherence-
enhancing interventions must be based on reasons for non-
adherence and be evaluated using accepted clinical and economic
quality criteria.
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OBJECTIVES: To study medication compliance patterns regard-
ing dosing, timing and adherence under real life conditions.
Using a new electronic blister pack system. METHODS: A total
of 37 volunteers from three study centers were each furnished
with an electronic blister holder (“monitor”) and three blister
packs containing 14 placebo capsules each (trial duration: six-
weeks). The monitor measured the disruption of conductive lines
printed on aluminum carrier foil under each capsule and stored
this information (date and time) for evaluation at the end of the
study. Patients had to take out one capsule daily in the morning
over the entire study period. Also patients received a CRF and a
radio-controlled clock such that date and time of the event could
be manually recorded by the patient as well. Data were consid-
ered accurate if the information stored in the monitor and the
corresponding CRF entries were within a time window of ±15
min. RESULTS: All recordings of the electronically stored infor-
mation matched the data documented on the CRFs. This indi-
cates the accurate documentation of the volunteers, as well as
the correct functioning of the monitors. Evaluation of the data,
however, showed a wide intra—as well as interindividual varia-
tion in the time patterns of the volunteers. Three clusters of 
time preference were detected—mornings, noon and late night.
Further, periods of non-compliance (“drug holidays”) as well as
lack of adherence (discontinuation of medication before the end
of the study period of six-weeks) could be documented. CON-
CLUSIONS: The use of the new electronic blister system
improves compliance measurement under real life conditions.
Combining compliance information with other outcome para-
meters will help in better quantifying and optimizing the impact
of patient compliance on clinical and economic outcomes under
real life conditions.
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OBJECTIVE: Chronic disease sufferers are particularly affected
by prescription copayment increases as they are faced with deci-
sions to switch to formulary alternatives or pay more to stay on
their current medication. The objective of this study was to eval-
uate the impact of increased prescription copayments as a result
of a change in formulary status on continuation rates of non 
formulary medications in multi-tiered pharmacy beneﬁt plans.
METHODS: Retrospective cohort study of chronic disease
patients from a health plan in the Western U.S. Individuals were
selected who were taking a medication that was being removed
from the health plan’s formulary and thus experienced increases
in their copayments for non formulary medications (n = 1244).
Two time periods were studied: the “pre” period before and the
“post” period after the increase in copayments. Adjusting for
demographics, chronic co-morbidities, medication use, Medicare
+ Choice status and percentage increase in copayment for non
formulary medications, Cox regressions were used to assess 
continuation rates for these medications. RESULTS: A clear 
relationship between increasing copayment differentials and con-
tinuation rates for non formulary medications in the post period
could not be established. In general those who experienced
higher copayment differentials (between 50–100%, 100–200%
and greater than 200%) were more likely to continue their non
formulary medication than those who experienced copayment
increases of 25–50% and less than 25%. CONCLUSIONS: Indi-
viduals confronted with increased copayments often switched
their medications to formulary alternatives. However, a clear
relationship could not be established between increasing copay-
ments and continuation behavior. Further research is needed to
determine if these switching behaviors results in inappropriate
medication behaviors such as complete discontinuation of drug
therapy due to the increased costs.
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OBJECTIVES: The economics theory of consumer behavior sug-
gests that the impact of cost on product purchasing decisions
depends on the perceived beneﬁts associated with that product.
However, this relationship has been neither demonstrated nor
quantiﬁed for patients taking chronic medications. The objective
of this study was thus to analyze the impact of cost on medica-
tion compliance (reﬁlls) among groups of individuals with dif-
ferent levels of perceived beneﬁts. METHODS: Patients new to
statin therapy were identiﬁed from the prescription database of
a national retail chain. The perceived beneﬁt of the statin med-
ication was measured on a scale of one (low) to seven (high) by
surveying randomly selected new patients. Compliance with the
medication regimen during the ﬁrst 12 months of statin therapy
was measured in terms of the Medication Possession Ratio
(MPR). Information on cost and (MPR) on randomly selected
patients was obtained from the retail chain prescription data-
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base. Data was analyzed using a CHAID (Chi-square automatic
interaction detection) technique. RESULTS: The average MPR
of the sampled population (n = 181) was 0.62. CHAID analysis
segmented the sample into groups at a perceived beneﬁt value of
3.85 and a cost of $19.50. Patients with a perceived beneﬁt
below 3.85 had a signiﬁcantly lower MPR (0.26, p < 0.000) 
than patients with a perceived beneﬁt over.3.5 (MPR = 0.66).
Among patients in the higher perceived beneﬁt group, those
paying more than $19.50 per prescription had a signiﬁcantly
lower MPR (0.54, p < 0.000) than patients paying less than
$19.50 (MPR = 0.78). However, cost had no impact among
patients with a lower perceived beneﬁt. CONCLUSIONS: Per-
ceived beneﬁt and cost signiﬁcantly affected medication compli-
ance. Individuals with a high perceived beneﬁt were further
impacted by cost; no such effect was observed in individuals with
low perceived beneﬁt.
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OBJECTIVES: To rationalize the clinical use of albumin in order
to reduce inappropriate subministration and minimize costs in a
300-beds community hospital. METHODS: A multidisciplinary
team composed by the Chief Medical Ofﬁcer, the Intensive Care
Unit Director, the Immunostransfusional Unit Director, the
Farmacy Director, elaborated a clinical practice protocol on 
the prescription of albumin and a speciﬁc form for it request 
to Farmacy. Clinical indications for albumin use were deﬁned
according to a method which combined a review of the medical
literature with experts points of view. First choice criteria were
paracentesis, bacterial peritonitis, plasmapheresys, liver-kidney
disease, liver transplant; second choice criteria were hypo-
volaemia, burns, haemolitical neonatal syndrome. Protocol dis-
semination and implementation started in October, 2003. The
method for assessing the impact was a pre-post analysis of the
discrepancies between recommendations and clinical practice
(2003-ﬁrst semester versus 2004-ﬁrst semester). Results were
tested by chi-square test (X2). RESULTS: A 55% decrease in 100
g/l-phials of albumin prescription was found in 2004 with
respect to 2003 (X2 = 211.92; df = 1; p < 0.001). In particular
the 25g/l- threshold for subministration was respected in 75.3%
cases in all. Signiﬁcative reduction of inappropriate utilization
was found in cirrosis patients (X2 = 22.28; df = 1; p < 0.001),
hypoalbuminaemia conditions (X2 = 23.31; df = 1; p < 0.005)
and haedema impairment (X2 = 87.09; df = 1; p < 0.001). The
expenditure for albumin decrease from 48.910€ ($65,510.05) to
21.629€ ($28,969.88) without any negative outcomes referred.
CONCLUSION: Shared multidisciplinary protocol signiﬁcantly
improved appropriateness of albumin utilization and expendi-
ture rationalization preserving positive outcome. It appeared to
be a simple health technology that improved hospital efﬁciency
in a short time. Multidisciplinary and sharing of information are
supposed to be the key tools for this success.
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OBJECTIVE: To describe a visually-friendly approach (Drug-O-
Gram) for summarizing patterns of drug use over time using
medications to treat two common disease conditions—arthritis
and hypertension. METHODS: Administrative claims data
(Medstat MarketScan) was used to identify hypertensive patients
newly treated with diuretics, angiotensin-receptor blockers
[ARB], or calcium-channel blockers [CCB]; and arthritis patients
newly treated with cyclooxygenase-2 [COX-2] inhibitors or 
traditional non-steroidal anti-inﬂammatory drugs [NSAID]).
Patients were then classiﬁed according to medication class use
during each subsequent day for one year. The Drug-O-Gram
plots the distribution of drug use over the follow-up period. Sta-
tistical smoothing was applied to the plots to help visualize
trends over time. Superimposed on the plots are plots of outpa-
tient medical costs impacted by medication use. RESULTS:
Among patients with hypertension, the percent of days on med-
ication was higher for ARBs (65%) compared to CCBs (59%)
and diuretics (48%). Additionally, outpatient medical payments
for ARB patients were 69% of diuretic and 56% of CCB out-
patient payments. Among patients with arthritis, discontinuation
was faster and persistency worse for traditional NSAIDs than for
the COX-2 inhibitors. CONCLUSIONS: The Drug-O-Gram
graphically summarizes drug use over time by ﬁtting graphical
smooths to daily averages. It then stacks these graphs to visual-
ize changes between medications. These plots convey more detail
of drug use patterns than commonly used discontinuation and
switching rates. Areas under the plots can be used to quantify
and analyze the amounts and changes of drug use over time. By
superimposing daily plots of other outcomes, one can assess their
relationship to drug use.
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OBJECTIVES: To examine the prevalence of drug noncompli-
ance among TRICARE beneﬁciaries, the reasons for it, costs
associated with unclaimed prescriptions, and how pharmacy fea-
tures inﬂuence compliance in the Military Health System (MHS).
METHODS: We conducted interviews with staff at six pharma-
cies, a telephone survey of 1214 TRICARE beneﬁciaries, and
analysis of pharmacy data. Pharmacy interviews provided infor-
mation on the average level of noncompliance and features dis-
tinctive to each site. We asked beneﬁciaries to report on their
prescription compliance in the year prior to the survey and
reasons for noncompliance. We used claims data to examine uti-
lization among noncompliers and the direct cost of unclaimed
prescriptions. RESULTS: After weighting survey responses at the
six study pharmacies, approximately 8% of beneﬁciaries failed
to pick up at least one prescription in the year before the survey.
Noncompliance was most prevalent among young, active duty
personnel and less so among older, retired beneﬁciaries. Non-
compliers were more likely than compliers to have had an emer-
gency room visit in the last year (12.3% versus 6.6%). The total
annual estimated costs of unclaimed prescriptions in additional
labor and discarded drugs is roughly $50,000, per 1,000,000
beneﬁciaries. The most common reasons for non-compliance
included long wait times at the pharmacy (11.1% of non-
compliers), the perception that the prescription was not needed
(18.5%), and patient forgetfulness (17.3%). The primary phar-
macy features that inﬂuence noncompliance include long wait
times, the dispensing process used at the pharmacy, patient
reminder calls, and providers not receiving automated messages
about non-compliant prescriptions. CONCLUSION: Policy rec-
